Celgene Corp (CELG)

119.27
NASDAQ : Health Care
Prev Close 119.27
Day Low/High 0.00 / 0.00
52 Wk Low/High 94.39 / 127.00
Avg Volume 4.27M
Exchange NASDAQ
Shares Outstanding 777.97M
Market Cap 92.92B
EPS 2.60
P/E Ratio 47.97
Div & Yield N.A. (N.A)

Latest News

Market Not Laced With Kool-Aid; Apple Could Become a Consumer-Products Company: Jim Cramer's View

Market Not Laced With Kool-Aid; Apple Could Become a Consumer-Products Company: Jim Cramer's View

Cramer shares his views on how tired he is of hearing about Kool-Aid, and wonders if Apple could be valued as a consumer-products company one day.

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Doug Kass shares his thoughts on Procter & Gamble, and wonders if the market is about to slip its moorings.

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.

Celgene Announces Positive Results From Phase III SUNBEAM Trial Of Oral Ozanimod In Patients With Relapsing Multiple Sclerosis

Celgene Announces Positive Results From Phase III SUNBEAM Trial Of Oral Ozanimod In Patients With Relapsing Multiple Sclerosis

Celgene Corporation (NASDAQ: CELG) today announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with...

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Some tried-and-true indicators show what's really going on with the market.

Celgene Could Have One More Powerful Move Higher

Celgene Could Have One More Powerful Move Higher

Celgene's rebound off the January lows could soon develop into a fresh move higher.

Chesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning Round

Chesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning Round

Jim Cramer's bullish on ZELTIQ Aesthetics, Chesapeake Energy, Priceline Group and more.

Why These Market Gains Are More Powerful Than Trump: Cramer's 'Mad Money' Recap (Monday 2/13/17)

Why These Market Gains Are More Powerful Than Trump: Cramer's 'Mad Money' Recap (Monday 2/13/17)

Jim Cramer says it's a sea change: It's not just about economic growth, it's about global growth without inflation.

Full Steam Ahead? Not So Fast

The market is a bit overbought to go along with all that giddiness.

Teva Claws Its Way Back With Earnings, Revenue Beat

Teva Claws Its Way Back With Earnings, Revenue Beat

The company had been free falling after CEO Erez Vigodman stepped down last week.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Celgene Corporation To Webcast At Upcoming Investor Conference

Celgene Corporation To Webcast At Upcoming Investor Conference

Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company.

House Panel to Take Up Trump's Call to Speed FDA Approvals

House Panel to Take Up Trump's Call to Speed FDA Approvals

Generics for drugs facing shortages or having few manufacturers is bill's focus.

Trump Investing: Listen, Don't Overreact

Trump Investing: Listen, Don't Overreact

Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.

Trump, at Biopharma Meeting, Pledges to 'Streamline' FDA, Cut Regulations but Wants Lower Prices

Trump, at Biopharma Meeting, Pledges to 'Streamline' FDA, Cut Regulations but Wants Lower Prices

Biotech and drugs stocks are soaring Tuesday after President Donald Trump met with CEOs of the biotech and pharma industries Tuesday.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Allergan, Starbucks, Citigroup: Doug Kass' Views

Allergan, Starbucks, Citigroup: Doug Kass' Views

Doug Kass shares his thoughts on Starbucks, and discusses what, if anything, Dow 20,000 means.

Celgene Receives Positive CHMP Opinion To Expand REVLIMID® (Lenalidomide) Indication As Monotherapy For The Maintenance Treatment Of Patients With Newly Diagnosed Multiple Myeloma (MM) After Autologous Stem Cell Transplantation

Celgene Receives Positive CHMP Opinion To Expand REVLIMID® (Lenalidomide) Indication As Monotherapy For The Maintenance Treatment Of Patients With Newly Diagnosed Multiple Myeloma (MM) After Autologous Stem Cell Transplantation

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted...

Celgene Shares Sink Despite 36% Earnings Growth

Celgene Shares Sink Despite 36% Earnings Growth

Celgene also acquired privately held biotech firm Delinia for an initial payment of $300 million and contingent, or future, payments of $475 million.

Market Recon: Let's Talk About Bonds for a Minute

Market Recon: Let's Talk About Bonds for a Minute

The yield on the 10-year Treasury bond walks a fine line between pleasure and pain.

Celgene Reports Fourth Quarter And Full-Year 2016 Operating And Financial Results

Celgene Reports Fourth Quarter And Full-Year 2016 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quarter and full-year of 2016.

Celgene To Acquire Delinia, Inc.

Celgene To Acquire Delinia, Inc.

Celgene Corporation (NASDAQ: CELG) and Delinia, Inc. ("Delinia"), a privately held biotechnology company developing novel therapeutics for autoimmune diseases, today announced that they have entered into an agreement for...

Rally Comes With an Asterisk

If you look more closely, it's not so impressive.

Three Health-Care Growth Plays

Three Health-Care Growth Plays

Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.

5 Reasons Why Celgene Should Buy Competitor Biogen

5 Reasons Why Celgene Should Buy Competitor Biogen

There are several reasons why Celgene should buy Biogen.

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

A merger would be smart, profitable ... and attention-grabbing.

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.